Human Immunodeficiency Virus Clinical Trial
— MONODOOfficial title:
An Interventional, One-arm, Open Label Pilot Study to Assess the Feasibility of Dolutegravir Monotherapy in Virologically Suppressed Patients on Conventional Triple Antiretroviral Therapy of Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors
Verified date | October 2017 |
Source | University Hospital, Geneva |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Current HIV treatment guidelines recommend a combination of drugs for the maintenance of antiretroviral therapy (ART). Simplification is considered critical to further scale-up of treatment, to support retention in care and to reduce costs. Dolutegravir is a once daily integrase inhibitor that shows very good tolerability, efficacy, and distinctive resistance profile. The researchers aim at investigating the feasibility of dolutegravir monotherapy in maintenance therapy. Briefly, 10 virologically suppressed patients for at least six months on conventional triple ART of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) will be switched to dolutegravir monotherapy for 24 weeks. The primary endpoint is the number of patients completing 24 weeks of dolutegravir monotherapy without experiencing virological failure.
Status | Completed |
Enrollment | 8 |
Est. completion date | September 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - HIV-1 infection; - Patient included in the Swiss HIV Cohort Study (SHCS); - = 18 years of age; - Virologically suppressed for at least 24 months on first line triple ART (changes for toxicity permitted) with at least 4 HIV-1 RNA measurements in plasma <50 copies/ml; - No history of previous failure on ART; - No documented antiretroviral drugs resistance; - No co-infection with Hepatitis B or C virus; - Effective contraception in women; - Willing to provide CSF and semen samples; - Written informed consent Exclusion Criteria: - HIV-2 infection; - Renal dysfunction (creatinine clearance <50ml/min); - aspartate transaminase or alanine aminotransferase >5x upper limit normal; - Concomitant use of carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's wort, rifampicin or metformin; - Previous AIDS defining conditions or active malignancy in the past five years; - Positive HIV viral load in CSF at baseline; - Known or suspected non-compliance; - Women who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospitals of Geneva, HIV unit | Geneva |
Lead Sponsor | Collaborator |
---|---|
Calmy Alexandra |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in immune activation from baseline to week 24 measured by highly sensitive C-reactive protein (mg/l) | week 24 | ||
Other | Change in immune activation from baseline to week 24 measured by cytokines (pg/ml) | week 24 | ||
Other | Change in immune activation from baseline to week 24 measured by d-dimers (microg/l) | week 24 | ||
Primary | Number of patients without virological failure defined as plasma HIV-1 RNA = 200 copies/ml on two consecutive measurements or positive HIV-1 RNA level in cerebrospinal fluid (CSF) at week 24 or before | week 24 | ||
Secondary | Quantification of the HIV-1 DNA reservoir in peripheral blood monocyte cells at baseline and week 24 | week 24 | ||
Secondary | Emergence of genotypic resistance in plasma HIV-1 RNA in case of virological failure | week 24 | ||
Secondary | Quantification HIV-1 RNA levels in the CSF and semen at baseline and week 24 | Lumbar puncture is optional at baseline | week 24 | |
Secondary | Change from baseline CD4 cell count from baseline at week 24 | week 24 | ||
Secondary | Adherence to medication at weeks 4, 8, 12, 16, 20, 24 | Number of participants with suboptimal adherence defined as more than 3 pills (10%) remaining from previous monthly visit OR missed more than one dose in a row OR missed dose more than once every two weeks | week 24 | |
Secondary | Lipidic profile changes from baseline at week 24 | week 24 | ||
Secondary | Body fat composition as measured by dual energy x-ray absorptiometry (DXA) scan at baseline and week 24 | week 24 | ||
Secondary | Change in bone mineral density from baseline to week 24 | Number of patients with normal bone density, osteopenia or osteoporosis as defined by DXA scans results | week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |